Search

Your search keyword '"Forster, Martin"' showing total 964 results

Search Constraints

Start Over You searched for: Author "Forster, Martin" Remove constraint Author: "Forster, Martin"
964 results on '"Forster, Martin"'

Search Results

101. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

104. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

106. Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development

107. Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review

108. 1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

109. 675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

113. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

116. A Randomized Controlled Trial of a Standardized Behavior Management Intervention for Students with Externalizing Behavior

118. Author response: Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development

119. Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial

122. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

123. Clinical development of new drug-radiotherapy combinations

124. Auf gut Klick! Über die Do's and Dont's der virtuellen Wissens- und Kulturvermittlung: Hintergründe und Praxisbericht zu Webinaren und Online-Führungen an der Österreichischen Nationalbibliothek.

125. Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts.

128. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System

130. A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

134. The Impact of COVID-19 on Clinical Nurse Specialists and Patients With Cancer:A Pan-Specialty Cross-sectional Survey

135. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience

136. CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC)

137. SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC)

138. Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma

139. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

140. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

141. Delivering Value for Money in Clinical Trials: Value-Adaptive Designs for Efficient Delivery of Publicly Funded Trials

142. sj-pdf-1-jad-10.1177_10870547221092120 – Supplemental material for Is Parents’ ADHD Symptomatology Associated With the Clinical Feasibility or Effectiveness of a Psychoeducational Program Targeting Their Children’s ADHD?

146. 359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

147. 543 Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation

148. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

149. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

150. Correction to: DNA methylation-based reclassification of olfactory neuroblastoma

Catalog

Books, media, physical & digital resources